Navigation Links
Statement from Ralph G. Neas, President and CEO, Generic Pharmaceutical Association, on the Front Page New York Times Story Regarding the Pre-emptive Strikes of Amgen/Genentech to Restrict Access to Affordable and Safe Biosimilars
Date:1/29/2013

WASHINGTON, Jan. 29, 2013 /PRNewswire-USNewswire/ --Today's story shines a light on what essentially is a pre-emptive strike by Amgen and Genentech designed to choke the flow of safe and affordable life-saving biologic medicines to patients even before these products have been approved by the Food and Drug and Administration (FDA).  This is unfortunate because it puts profits ahead of the patients who need these treatments but many times cannot get them because of their prohibitively high cost.

The efforts highlighted in the Times story are doubly worrying for state legislators because not only will they slow availability of safe, effective and more affordable therapies to patients, but they also will dramatically decrease the much-needed cost savings that biosimilars will provide. At a time when legislators are desperately seeking ways to keep their state fiscally sound, these bills will encourage needless and wasteful spending on name brand therapies even after FDA-approved lower cost biosimilar products become available.

While in the guise of supporting biosimilar efforts, Amgen and Genentech are making every effort to limit consumer and patient access to safe and effective biosimilars in the future.

Biosimilar medicines, which are less costly versions of brand-name biologics, have been used safely in Europe for nearly seven years.  However, these affordable treatments are not yet available in the U.S.  But under new federal laws, the FDA now is developing regulations that will allow for the approval and use of biosimilars here at home.  Make no mistake: patient safety is paramount both for the FDA and for the companies that will make these medicines.  In fact, many of the companies who are working to develop biosimilars are the same companies now making brand name biologics.

As the Times story correctly notes, efforts by brand companies to erect barriers to competition from lower cost generic versions of their drugs have been going on for decades.  But as is true with traditional prescription drugs, competition from safe, effective and more affordable biosimilars will, in the coming years, provide patients the savings they need while delivering the lifesaving therapy they depend upon.

According to an analysis by IMS Health published August 2, 2012, generic medicines saved the U.S. health care system more than $1 trillion over the past decade, $192 billion in 2011 alone.  We are confident that the use of safe and effective bisimilars will achieve similar savings.

GPhA represents the manufacturers and distributors of finished generic pharmaceuticals, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals fill 80 percent of the prescriptions dispensed in the U.S. but consume just 27 percent of the total drug spending. Additional information is available at gphaonline.org.

Generic Pharmaceutical Association - 777 Sixth Street, NW, Suite 510 - Washington, D.C. 20001


'/>"/>
SOURCE Generic Pharmaceutical Association
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Icahn Issues Statement Regarding Amylin Pharmaceuticals
2. American Society of Hematology Statement on Senate Passage of Prescription Drug User Fee Act (PDUFA)
3. American Society of Hematology Statement on House Passage of Prescription Drug User Fee Act (PDUFA)
4. Millennium Laboratories Wins Lawsuit: Ameritox Advertisements Regarding Rx Guardian and Rx Guardian CD Contain Literally False Statements
5. Statement from the Cystic Fibrosis Foundation on Passage of the EXPERRT Act in House of Representatives
6. Lilly Statement on PDUFA Vote by Senate
7. Statement from the Cystic Fibrosis Foundation on Passage of the EXPERRT Act in the U.S. Senate
8. Lilly Statement on Affordable Care Act Ruling by Supreme Court
9. Statement from Mary Vogt, President of Home Access Health Corporation, manufacturer of the Home Access HIV-1 test system, the only over-the-counter HIV test previously approved by the FDA for at-home use.
10. CRE Statement on "Inherent Reasonableness" for Retail Pharmacy Diabetic Supplies
11. Johnson Health Tech Statement on Lance Armstrong
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research ... MEMS Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data ... analysis. Assessment of major trends with potential impact on the ... analysis of market segmentation which comprises of sub markets, regional ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 If ... Leaders Scholarship is any indication, the future is in ... at www.diabetesscholars.org by the Diabetes Scholars Foundation ... the way of academic and community service excellence. ... since 2012, and continues to advocate for people with ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (United States, China, Japan, Brazil, United Kingdom, Germany, France, ... Surgical Procedure Volumes: ... provides surgical procedure volume data in a geographic context. ... analysis of growth drivers and inhibitors, including world population ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out of ... verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all ... brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary ...
(Date:6/24/2016)... ... , ... People across the U.S. are sharpening their pencils and honing their ... in which patients and their families pay tribute to a genetic counselor by nominating ... of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, ...
(Date:6/24/2016)... Las Vegas, Nevada (PRWEB) , ... June 24, ... ... their Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and ... The Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer ...
(Date:6/24/2016)... ... 24, 2016 , ... Venture Construction Group (VCG) sponsors Luke’s Wings ... 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. ... service members that have been wounded in battle and their families. Venture Construction Group ...
Breaking Medicine News(10 mins):